Therapeutic Value of an Integrin Antagonist in Prostate Cancer

E-ISSN： 1873-5592|17|3|321-327

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.3, 2016-03, pp. : 321-327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prostate cancer: therapeutic patent review

By Sepp-Lorenzino L. Slovin S.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 12, 2000-12 ,pp. : 1833-1842

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Targets for Metastatic Prostate Cancer

Current Drug Targets, Vol. 4, Iss. 3, 2003-04 ,pp. : 251-261

Bentham Science Publishers

Access to resources Recommend Favorite

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer

By Mongiat-Artus Pierre Teillac Pierre

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2171-2179

Informa Healthcare

Access to resources Recommend Favorite

New Agonist- and Antagonist-based Treatment Approaches for Advanced Prostate Cancer

By Xu Y Jiang YF Wu B

The Journal of International Medical Research, Vol. 40, Iss. 4, 2012-07 ,pp. : 1217-1226

Field House Publishing

Access to resources Recommend Favorite

The androgen receptor as a therapeutic target in prostate cancer

By Visakorpi T.

Expert Opinion on Therapeutic Targets, Vol. 4, Iss. 1, 2000-02 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite